2022 will be a key year for the pandemic. Not only will there be more vaccines, but there will also be data on the evolution of the virus in those vaccinated, on new strains if they arise, and on how many of the symptoms affect the different age groups. Not to mention vaccine studies in babies, children, adolescents, which continue to advance.
And it is with regard to vaccination, where the CSIC scientist Vicente Larraga, has been interviewed in the Hoy por Hoy program of Cadena SER. He is one of the three CSIC researchers who are leading the development of a vaccine against COVID in our country, he has assured in an interview that the suspension of human trials of one of the Spanish vaccines against coronavirus it was “a surprise”. It is necessary to know in detail the official statement of the Spanish Medicines Agency.
About the suspended study
“The Spanish Agency is practically the European Agency and that gives value because any step that is achieved is guaranteed.”
Research in mice, then hamsters, then humans
The project vaccine led by Larraga is finishing the preclinical phase, with very good results in mice, in which 100% protection has been observed without any type of symptoms. Now the investigation will go to another animal, hamster and, if all goes well, request the Spanish Medicines Agency to start Phase 1 of the human trial.
Why the trial will not be done in Spain
The scientist has affirmed that the studies of phase 3 and 4 of the next vaccines, the previous step to be approved, will not be able to be carried out in Europe because there is already a large population with the complete regimen. Therefore is optimistic for next year, due to the progress of more research around the world, and by the fact of analyzing new research and studies with more vaccines of all kinds, trusting that get up to four better vaccines than now.